![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PathGroup Launches Cancer-Specific Testing Product
PathGroup Launches Cancer-Specific Testing Product
June 18, 2015
PathGroup is launching its cancer-specific SmartGenomics testing platform, which features diagnostic panels targeting lung, colon, brain, thyroid and melanoma/GIST cancers in newly diagnosed patients.
The product offers an individualized genomic baseline of a patient’s cancer, linking the panels to specific treatment options, the company says.
In addition, the product is comprised of 85 gene panels for relapsed or refractory tumors and boasts a genome array analysis that includes more than 22,000 genes.
Brentwood, Tenn.-based PathGroup was founded in 1965. — Jason Scott
Upcoming Events
-
21Oct